

Yves D Pastore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10941903/publications.pdf>

Version: 2024-02-01

19
papers

656
citations

933447

10
h-index

996975

15
g-index

19
all docs

19
docs citations

19
times ranked

740
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality of life is an important indication for secondâ€line treatment in children with immune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29023.	1.5	4
2	Characterization of the severe phenotype of pyruvate kinase deficiency. <i>American Journal of Hematology</i> , 2020, 95, E281.	4.1	8
3	Changes in hair cortisol and self-reported stress measures following mindfulness-based stress reduction (MBSR): A proof-of-concept study in pediatric hematology-oncology professionals. <i>Complementary Therapies in Clinical Practice</i> , 2020, 41, 101249.	1.7	3
4	Fatigue in children and adolescents with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2020, 191, 98-106.	2.5	18
5	Duration of neonatal oxygen supplementation, erythropoiesis and blood pressure in young adults born preterm. <i>Thorax</i> , 2020, 75, 494-502.	5.6	12
6	Secondâ€line treatments in children with immune thrombocytopenia: Effect on platelet count and patientâ€centered outcomes. <i>American Journal of Hematology</i> , 2019, 94, 741-750.	4.1	37
7	Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. <i>Haematologica</i> , 2019, 104, e51-e53.	3.5	46
8	Physician decision making in selection of secondâ€line treatments in immune thrombocytopenia in children. <i>American Journal of Hematology</i> , 2018, 93, 882-888.	4.1	30
9	Developing professional caregiversâ€™ empathy and emotional competencies through mindfulness-based stress reduction (MBSR): results of two proof-of-concept studies. <i>BMJ Open</i> , 2018, 8, e018421.	1.9	29
10	Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. <i>Blood</i> , 2018, 131, 2183-2192.	1.4	121
11	A 15-year-old boy with sickle cell disease, chest pain and respiratory distress. <i>Cmaj</i> , 2017, 189, E1529-E1530.	2.0	0
12	Clinical Characteristics and Quality of Life of Children with ITP Starting Second Line Treatments: Data from the ITP Consortium of North America ICON1 Study. <i>Blood</i> , 2016, 128, 249-249.	1.4	7
13	Physician Factors Determining Treatment Decisions in Selecting Second Line Agents for Pediatric ITP. <i>Blood</i> , 2016, 128, 1008-1008.	1.4	0
14	Blood Group Genotyping to Prevent Alloimmunization in Children with Sickle Cell Disease. <i>Blood</i> , 2016, 128, 2486-2486.	1.4	0
15	Comparison of Bleeding Tools in a Cohort of Pediatric Patients with ITP: Data from the Pediatric ITP Consortium of North America ICON1 Study. <i>Blood</i> , 2016, 128, 4752-4752.	1.4	0
16	Iron Overload Is Highly Prevalent in All Disease Severity States in Pyruvate Kinase Deficiency (PKD). <i>Blood</i> , 2016, 128, 2430-2430.	1.4	1
17	The worldwide distribution of the VHL 598C>T mutation indicates a single founding event. <i>Blood</i> , 2004, 103, 1937-1940.	1.4	67
18	Mutations in the VHL gene in sporadic apparently congenital polycythemia. <i>Blood</i> , 2003, 101, 1591-1595.	1.4	133

#	ARTICLE	IF	CITATIONS
19	Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood, 2003, 101, 3294-3301.	1.4	140